Aytu BioPharma Revenue Grows on EXXUA Launch in Fiscal 2026 Results

Key Facts

In a move reflecting the successful commercial execution of its new product pipeline, Aytu BioPharma reported its fiscal year 2026 financial results. According to reports, fourth-quarter net revenue increased by 6.4% to $16.1 million, up from $15.1 million in the prior-year period. This growth was primarily driven by the commercial launch of EXXUA, which generated $6.6 million in total fiscal 2026 revenue, with $3.9 million occurring in the final quarter alone.

The results highlight continued growth within the specialty pharmaceutical sector, as operational data showed a 138% sequential increase in EXXUA prescriptions compared to the third quarter. Regarding the company's financial position, reports indicate that Aytu BioPharma maintained a cash balance of $26.3 million as of June 30, 2026, providing a liquidity buffer for ongoing commercial activities.

In the markets, AYTU shares stood at $2.13 at the close of September 21, 2026, having traded within a range of $2.1 to $2.2 during that session. Investors are now looking toward the sustainability of prescription growth and the company's ability to maintain positive Adjusted EBITDA as the commercial rollout of its key products progresses.